Breo Ellipta 25 ug/1

Fluticasone furoate and vilanterol, the active ingredient in Breo Ellipta, is a combination inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA) presented as a 25 µg per inhalation powder for respiratory use. It is used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in eligible patients.

GNH USA supplies Breo Ellipta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Breo Ellipta is a combination medication used to manage respiratory conditions. It is primarily prescribed for the following conditions:

- Asthma: Helps control and prevent symptoms such as wheezing, shortness of breath, coughing, and chest tightness. - COPD: Reduces inflammation and improves airflow in the lungs to manage symptoms like chronic bronchitis and emphysema.

Breo Ellipta may cause various side effects, ranging from common to serious.

Common Side Effects: - Headache: Mild to moderate pain in the head. - Throat irritation: Soreness or discomfort in the throat. - Nasal congestion: Stuffy or runny nose. - Back pain: Discomfort or pain in the back. - Joint pain: Aching or discomfort in the joints. - Sinusitis: Inflammation of the sinuses. - Oral thrush: Fungal infection in the mouth. - Cough: Persistent coughing.

Serious or Rare Side Effects: - Worsening of breathing problems: Severe asthma attacks or COPD exacerbations. - Pneumonia: Lung infection, especially in COPD patients. - Cardiovascular effects: Increased heart rate, palpitations, or changes in blood pressure. - Eye problems: Increased risk of glaucoma or cataracts. - Osteoporosis: Weakened bones. - Hypokalemia: Low potassium levels in the blood. - Allergic reactions: Hives, rash, or swelling of the face, lips, or tongue.

Breo Ellipta should be used with caution and under medical supervision. Important precautions include:

- Not for rescue use: Do not use during sudden breathing problems; a rescue inhaler is required for acute symptoms. - Regular monitoring: Frequent eye exams and bone density tests may be needed due to the risk of glaucoma, cataracts, and osteoporosis. - Infections: Increased risk of pneumonia in COPD patients; monitor for signs of infection. - Cardiovascular conditions: Use cautiously in patients with heart conditions, hypertension, or arrhythmias. - Hypokalemia: Monitor potassium levels regularly, especially in high-risk patients. - Storage: Store at room temperature and away from sunlight, excess heat, and moisture. Keep in the foil tray and out of reach of children. Dispose of the inhaler 6 weeks after removing it from the foil overwrap or when the dose indicator reads 0, whichever comes first.

Breo Ellipta may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: Can increase the risk of systemic side effects of fluticasone and vilanterol. - Beta-blockers: May reduce the effectiveness of vilanterol and worsen breathing problems. - MAO inhibitors: Can increase the risk of cardiovascular side effects. - Tricyclic antidepressants: May enhance the cardiovascular effects of vilanterol. - Monoamine oxidase inhibitors: Can increase the risk of adverse cardiovascular effects.

Moderate Interactions (Monitor Closely): - Other corticosteroids: May increase the risk of systemic side effects. - Diuretics: Can increase the risk of hypokalemia. - Anticholinergics: May enhance the bronchodilator effects but also increase the risk of side effects. - Theophylline: Can increase the risk of cardiovascular side effects and hypokalemia.